QIAGEN N.V. and Eli Lilly and Co. have entered a collaboration to develop assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. QIAGEN will use its multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.       This is the companies’ fourth project. In 2011, QIAGEN and Lilly partnered to develop a companion diagnostic that evaluates a gene mu...